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Abstract
Ubiquitin-dependent proteolysis is a major mechanism that downregulates misfolded proteins or those that have finished a programmed task.
In the last two decades, neddylation has emerged as a major regulatory pathway for ubiquitination. Central to the neddylation pathway is the
amyloid precursor protein (APP)-binding protein APP-BP1, which together with Uba3, plays an analogous role to the ubiquitin-activating
enzyme E1 in nedd8 activation. Activated nedd8 covalently modifies and activates a major class of ubiquitin ligases called Cullin-RING ligases
(CRLs). New evidence suggests that neddylation also modifies Type-1 transmembrane receptors such as APP. Here we review the functions of
neddylation and summarize evidence suggesting that dysfunction of neddylation is involved in Alzheimer’s disease.
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Introduction
Ubiquitination tags a target protein for proteolysis when it is misfold-
ed or when it finishes a programmed task. It also plays a role in cell
signaling depending on the ubiquitin-linkage type. Ubiquitination is
important in maintaining normal cell functions in all types of cells,
most relevantly those in the brain. Evidence accumulated in recent
years suggests that ubiquitination dysfunction underlies major neuro-
degenerative diseases. This evidence not only includes the presence
of insoluble proteins such as tau tangles and amyloid plaques in Alz-
heimer’s disease (AD), but also the critical roles certain proteins play
in the ubiquitination pathway. One such important pathway protein is
APP-binding protein 1 APP-BP1 (BP1), which activates CRLs and reg-
ulates Type-1 transmembrane receptor signaling via neddylation.
Neddylation has been under intense scrutiny in cancer research (see
recent review by Soucy et al. [1]). This current review instead focuses
on the emerging field that studies the neuronal functions of APP-BP1
(BP1) and its downstream effectors. We highlight the areas of
research that suggests that the BP1-activated neddylation pathway is
dysfunctional in AD.
BP1 was first cloned by its interaction with the C-terminus of APP
in 1996. It is homologous to Arabidopsis auxin-resistant gene 1
(AXR1) [2, 3]. The ubiquitin-like protein nedd8 was first cloned as a
developmentally down-regulated gene expressed in neural precursor
cells in 1993 [4]. Both BP1 and AXR1 are homologous to the N-termi-
nus of the ubiquitin-activating enzyme E1 except that they lack the
active site cysteine residue required for ubiquitin conjugation and
present in the C-terminus of E1. In 1998, Ula1, the yeast counterpart
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of BP1 and AXR1, was shown to form a heterodimer with Uba1 (anal-
ogous to mammalian Uba3) to activate Rub1 (related to ubiquitin-1,
analogous to nedd8) [5]. Based on in vitro studies, BP1 was
proposed to be a member of the nedd8-conjugtion pathway [6, 7].
In vitro, BP1 together with Uba3 that has an active cysteine and the
ATP binding site, behaves like the ubiquitin-activating enzyme E1 and
activates nedd8 (Fig. 1). After activation, nedd8 forms a thiolester
bond with the nedd8-conjugating enzyme Ubc12. Subsequently,
nedd8 is covalently coupled to the substrate in a step mediated by a
nedd8 ligase such as the RING domain protein Rbx1 [8, 9], Rbx2
[10], and Tfb3 [11]; an IAP (inhibitor of apoptosis protein) [12, 13];
and Dcn1 (the defective in Cullin neddylation 1) or Dcn1-like protein
[14, 15]. The BP1/Uba3 bipartite activating enzyme of nedd8 is also
known as NAE (the nedd8-activating enzyme). The series of reactions
that lead to the covalent conjugation of nedd8 to the substrate is now
known as neddylation.
The function of BP1 in cell growth was first characterized in ts41
cell line, a mutant of V-79 cell line. These cells undergo successive
DNA replication without cell division at the non-permissive tempera-
ture [16]. In 1992, temperature-shift experiments by Handeli and
Weintraub confirmed that the ts41 gene product promotes entry into
mitosis but also discovered that it inhibits entry into S phase [17]. An
informal communication in 1997 suggests that the ts41 gene encodes
the hamster BP1 gene [18]. In 2000, we showed that human BP1 res-
cues the ts41 gene defect at the S-M checkpoint in a manner depen-
dent on the neddylation pathway [19]. This study provided the first
evidence that inhibition of BP1 causes cell death, suggesting that it is
a promising target for cancer treatment. A small molecule inhibitor of
NAE called MLN4924 was subsequently developed for cancer growth
inhibition [20]. Like in ts41 cells at the non-permissive temperature,
MLN4924 treatment causes apoptotic death in human tumour cells
by deregulating S-phase of the cell cycle [1].
Overview of the ubiquitination-
proteasomal pathway
Ubiquitin is a conserved 76-amino acid protein that covalently binds
to lysine residues in target proteins and to itself via the ubiquitination
pathway [21, 22]. The ubiquitination pathway is carried out through
the actions of three enzymes: E1 (the ubiquitin-activating enzyme), E2
(the ubiquitin-conjugating enzyme), and E3 (the ubiquitin ligase)
(Fig. 1). The E1 hydrolyzes ATP to form a thiolester bond with the C-
terminal glycine of ubiquitin and transfers the activated ubiquitin to a
cysteine residue in E2. The E2-ubiquitin can either bind to E3 to
directly transfer ubiquitin to a substrate protein, or transfer the ubiqu-
itin to E3 to form an E3-ubiquitin intermediate and then transfer the
ubiquitin to the substrate. When a protein is ubiquitinated, the C-ter-
minus of ubiquitin becomes conjugated to a lysine on the substrate
protein by an isopeptide bond. Ubiquitination can repeat several times
to attach additional ubiquitin molecules to the lysine residue of a for-
mer ubiquitin, which introduces an ubiquitin chain onto the substrate
protein [23]. Polyubiquitin chains linked by Lys-48 are essential for
26S proteasome recognition, which leads to degradation of the sub-
strate by the proteasome [24]. Polyubiquitin chains linked by Lys-6
inhibit ubiquitin-dependent proteolysis [25]. Membrane receptor
monoubiquitination tags the receptor for endocytosis and degradation
in the lysosomes [26]. Monoubiquitination of histones is usually
associated with signaling and structural marking [27]. Lys-63-linked
polyubiquitin chains are involved in signaling [28] and also mark a
receptor for endocytosis and lysosomal degradation [29, 30]. The
polyubiquitin chain can be disassembled by the activity of deubiquiti-
nating enzymes and the released ubiquitin is reused in the next ubiq-
uitination cycle [31]. The 26S proteasome is responsible for a large
fraction of the regulated protein degradation in eukaryotic cells.
Activation of CRLs by neddylation
E3s control the specificity of proteolysis by recognizing specific sub-
strates through protein-protein interactions. They comprise a diverse
family of proteins or protein complexes that can be distinguished
based on the type of the interaction domain (RING domain, U-box
domain, or HECT domain) used to bind E2 ubiquitin-conjugating
enzymes and whether they act as a single subunit or multisubunit
complex [32]. A major class of RING domain E3s is the multisubunit
ubiquitin-ligase CRLs, which consist of a scaffolding Cullin protein, a
zinc-chelating RING protein Rbx1 or Rbx2, and a substrate-recogni-
tion subunit. In CRLs, the N-terminus of Cullins interacts with Cullin-
specific substrate-recognition subunits, usually via adaptor proteins
[33, 34]. Seven Cullins (1, 2, 3, 4A, 4B, 5, and 7) in mammalian cells
form about 200 unique CRLs. CRLs play essential roles in cell signal-
ing as indicated by their enrichment in protein networks [35] and
hundreds of substrates [36]. Figure 1 shows a diagram of the well-
characterized Cullin1 (Cul1) CRL (also known as SCF complex)
consisting of Cul1, the RING protein Rbx1, the adaptor Skp1, and the
F-box (Fbx) protein bTrCP1. This SCF complex recognizes phosphor-
ylated b-catenin for ubiquitination after it binds to bTrCP1 [33].
Fig. 1 Neddylation activates ubiquitination of E3 ligase CRLs. A typical
SCF complex (purple) is used as an example of a CRL. The activity of
CRL is controlled by two major pathways: 1) ubiquitin (Ub) is activated
by E1 and transferred to Cul1 by E2, and 2) Cul1 is covalently modified
by Nedd8 (N8) via the BP1-activated neddylation pathway. Neddylation
changes Cul1 into its active conformation for ubiquitination of the target
protein b-catenin, which binds to the substrate receptor bTrCP1. Skp1
is the adaptor that bridges Cul1 and bTrCP1. The neddylation pathway
is also regulated by COP9, CAND1, and ASPP2. Green arrows indicate
recycling of the components.
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The central role of BP1 is to initiate the cascade of reactions that
neddylates Cullins and activates CRLs. Nedd8 is an 81 amino acid
protein 60% identical and 80% homologous to ubiquitin [4]. Imma-
ture nedd8 is processed to its mature, 76 amino acid form by DEN1,
which removes 5 amino acids from its C-terminal tail [37]. Nedd8 is
activated by the heterodimer BP1/Uba3 [5–7]. Activated nedd8 cova-
lently binds to a conserved lysine residue located in the C-terminal
Cullin domain in Cullin proteins. Neddylation of Cullins activates CRLs
by inducing a conformational change in the C-terminus of the Cullin
that promotes ubiquitin transfer to the substrate for ubiquitination
[38–40]. Cullin neddylation depends on the assemblies of the CRL
complex including the RING protein [41] and the substrate [42–45].
CRLs are often assembled and poised for activation by neddylation
upon signaling [35].
The best characterized CRL is the SCF complex, in which Cul1
serves as a scaffold and binds Rbx1 to its C-terminus and Skp1 to its
N-terminus [33] (Fig. 1). Skp1 in turn interacts with the F-box (Fbx)
motif at the N-terminus of the Fbx protein in the SCF complex [46].
The C-termini of Fbx proteins contain protein-protein interaction
domains including WD-40, KELCH and leucine-rich repeat domains
[47]. These domains can recruit specific substrates to the SCF com-
plex. In 293T cells, about 70% of Cul1 is assembled with Skp1 and
presumably Fbx proteins, independent of the neddylation status [35].
In mammals, about 70 genes encode Fbx proteins [47, 48]. It is well-
established that SCF downregulates the signaling molecule b-catenin.
Deletion of Uba3 [49] or PS1 [50] in mice both result in b-catenin
accumulation. Similarly, b-catenin is significantly increased in the
hippocampal neurons of APP knockout (KO) mice [51]. The degrada-
tion of b-catenin is mediated by BP1 since inactivating BP1 leads to
its accumulation (Y. Chen unpublished data).
Neddylation regulators
Neddylation itself is regulated by several pathways that all affect CRL
activity (Fig. 1). The current model is that the dynamic cycling of
neddylation and deneddylation is required for CRL activity [52]. Like
neddylation, the COP9 signalosome (CSN) and CAND1 positively
regulate CRL activity in vivo [34, 53, 54]. CSN is an evolutionarily
conserved complex consisting of eight subunits with similarity to the
19S regulatory particle of the 26S proteasome [34, 53–57]. CSN
physically interacts with neddylated Cullins and proteolytically cleaves
the isopeptide bond between nedd8 and the Cullin [56, 58, 59]. The
deneddylation reaction is mediated by the zinc metalloprotease CSN5
(also known as Jab1) [59], but loss of other CSN subunits also leads
to destabilization of the entire CSN complex, causing severe develop-
mental defects in plants [55, 60]. Deneddylation of Cullins by CSN
prevents the autocatalytic instability of Cullin substrate-specific adap-
tors and subunits [61, 62]. CSN appears to differentially regulate
Cullins since more CSN is bound to Cul4B than Cul1 under steady-
state conditions in 293T cells [35].
Unlike CSN that binds to neddylated Cullins, CAND1 (Cullin-
associated and neddylation-dissociated 1) interacts exclusively with
unneddylated Cullins [63–65] (Fig. 1). Similar to the manner of
regulation by CSN, both decreased and increased CAND1-Cul1
interactions impaire the function of SCF complexes in plants [66]. In
C. elegans, cand-1 mutants have phenotypes associated with the loss
of the SCF complex but lack phenotypes associated with other spe-
cific CRLs [67]. Only a small fraction of Cullins are associated with
CAND1 [35]. These findings suggest that CAND1 regulates a subset
of Cullins and of other currently unknown regulatory mechanisms
may exist.
ASPP2 (apoptosis-stimulating and p53-binding protein-2) is
another CRL regulator [68]. ASPP2, also known as 53BP2 or Bbp, is
encoded by TP53BP2 and first cloned as a p53-binding protein [69].
The C-terminus of ASPP2 consists of a proline-rich domain, two
ankyrin repeats, and an SH3 domain. Bcl2 and p53 bind ASPP2 com-
petitively to the region that contains the ankyrin repeats and the SH3
domain [70]. ASPP2 interacts with BP1 at two different sites, one
near the N-terminus within amino acids 332-483, and the second
within the C-terminal amino acids 693–1128 [68]. In HeLa cells,
ASPP2 decreases the levels of Cul1 whereas the N-terminal fragment
of ASPP2 stabilizes Cul1 [68], which suggests that ASPP2 downregu-
lates Cul1 through the N-terminal domain and that the N-terminal
fragment of ASPP2 has a dominant-negative effect. A previous study
shows that ASPP2 expression impedes cell cycle progression at G2/
M in HEK293 cells [70]. Since ASPP2 interacts with and opposes the
effect of BP1 in the cycle progression [17, 19], inhibition of neddyla-
tion by ASPP2 is probably the underlying mechanism of ASPP2-medi-
ated cell cycle inhibition and tumour suppression, which was recently
reviewed in [71]. We have found that the N-terminal fragments of
ASPP2 protect neurons from apoptosis by inhibiting DNA synthesis
induced by BP1 overexpression [68]. However, the physiological
function of ASPP2 in neurons remains to be determined.
Neddylation in APP proteolysis and
signaling
Besides Cullins, nedd8 modifies multiple lysine residues in APP and
the EGF receptor (EGFR) in the cytoplasmic domain [72, 73]. The
function of APP is under intense investigation due to its involvement
in AD (for recent reviews, see Zheng and Koo [74] and Zhang et al.
[75]). EGF stimulates EGFR neddylation, which enhances subsequent
ubiquitination and sorting of the receptor for degradation [72]. Like
EGFR, neddylation appears to regulate APP endocytosis and degrada-
tion although it is not clear if ubiquitination is also involved.
APP is neddylated in all the lysine residues in the APP intracellular
domain (AICD) [73] (Fig. 2A). Neddylation of APP is most likely due
to the interaction with BP1 since the lysine residues are within the
BP1-binding sites in APP [49, 76, 77]. The positioning of these lysine
residues suggest that they play important roles in APP function and
processing. Three neddylated lysines are found near the c-secretase
cleavage site. Interestingly, the other two lysines are located at an
equal distance from Y682. Among the five lysine residues, K649, K676,
and K688 are conserved in APLP2, whereas only K650 is conserved in
APLP1 (Fig. 2B). In primary neurons, acute BP1 expression downre-
gulates APP, has no significant effect on APLP1, and shows a poten-
tial effect in stabilizing APLP2 [76]. Besides BP1, many other proteins
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have been found to bind to AICD of APP, but it is not known if these
other binding proteins play a role in APP neddylation. For reviews of
the other binding partners of APP in AICD, refer to King and Turner
[78] and Kerr and Small [79].
APP is sorted to the lysosome for degradation after internalization
[80]. We have shown that exogenous expression of a familial AD
mutant of APP in neurons causes apoptosis and enlargement of early
endosomes, and increases receptor-mediated endocytosis via a path-
way dependent on the binding of BP1 to APP [80]. Downregulation of
BP1 that inhibits neddylation, results in the accumulation of APP, the
b-secretase-cleaved C-terminal fragment of APP, and Ab in primary
neurons [76]. These data suggest that neddylation of APP signals for
APP degradation via endocytosis.
Receptor endocytosis attenuates receptor signaling. It has been
shown that neddylation of AICD inhibits APP signaling by reducing
the interaction between APP and FE65 [73]. The tyrosine residue Y687
in the NPTY motif regulates rapid APP turnover although it does not
appear to be an internalization signal [81]. A recent study shows that
Y682 is indispensible for the essential function of APP in developmen-
tal regulations [82]. Perhaps neddylation of APP involves a conforma-
tional change in this region that affects the tyrosine phosphorylation,
stability, and signaling of APP.
Dysfunction of neddylation in AD
Neddylation is a delicate biological balance of the cell as demon-
strated by the effects of CSN and CAND1. Decreased or increased
levels of these regulatory molecules both impair CRL activities. It is
expected that BP1 manipulations would display similar complexities.
In primary neurons, overexpression of BP1 tips the balance to a direc-
tion that induces apoptosis, which involves cell cycle reactivation in
neurons [19, 49]. Endogenous BP1 protein and mRNA expressions
are abundant in some hippocampal pyramidal cells and dentate gran-
ule cells in the brain [77] (Fig. 3A). This suggests that BP1 has a
physiological function in these cells, which may be mediated by
Cullins and membrane receptors including APP and EGFR as men-
tioned above. SCCRO (squamous cell carcinoma-related oncogene)
also known as DCUN1D1, is a Dcn1-like protein and functions as a
ligase for nedd8 in the neddylation pathway [83]. In a recent
association study, the GG genotype of DCUN1D1 single nucleotide
polymorphism (SNP) was found to be a risk factor for the develop-
ment of frontotemporal lobar degeneration, carrying a fourfold
increased risk association [84]. This along with our previous studies
suggests that the BP1 pathway plays a pivotal role in the nervous
system.
Neddylation has been found to be deregulated in AD. In human
brain tissues, BP1 protein levels are elevated in the Triton-insoluble
and SDS-soluble fraction in AD tissues compared to that in age-
matched controls [19, 49]. In addition, AD conditions change
nedd8 localization. In normal hippocampal pyramidal cells and
granule cells, nedd8 is located in the nucleus, but in AD hippocam-
pal neurons, most nedd8 immunostaining is present in the cyto-
plasm (Fig. 3B) [49]. Anti-nedd8 stains neurofibrillary tangles and
senile plaques from patients with AD [85, 86]. Moreover, it has
been shown that the tau in the tangles is polyubiquitinated [87].
Evidence in the literature also shows that nedd8 can be erroneously
incorporated into ubiquitin chains by the ubiquitination enzymes,
which may occur under stress conditions and when the nedd8/
ubiquitin ratio is increased [88, 89]. It is conceivable that errone-
ous nedd8 incorporation into tau ubiquitination may also occur due
to elevated cytoplasmic nedd8 in AD neurons. Currently, we are
investigating if increased nedd8/ubiquitin ratio will lead to impaired
function of the targeted proteins such as tau. A potential patho-
genic mechanism involving faulty neddylation may underlie the
major pathological features of AD.
APP undergoes c-secretase cleavage to generate Ab. Presenilin is
the enzymatic component of the c-secretase complex that makes the
second cut of APP in the production of Ab [90]. We have shown that
APP, BP1, and PS1 co-migrate to a Triton-insoluble, low density,
lipid-raft fraction in brain protein extracts [49, 76]. This fraction of
lipid rafts mediates Ab42 genesis [91]. Lipid rafts consist of the fully
assembled c-secretase complex [92]. Besides interacting with APP,
BP1 also interacts with Presenilin [76]. This tripartite interaction not
only affects signaling as shown by b-catenin regulation [49–51], but
also regulates APP processing [76, 90]. BP1 knockdown stabilizes
PS1-CTF [76], which appears to be caused by the reduced activity of
a SCF complex since BP1 activates SCF by modifying Cul1 with
nedd8. In C. elegans, the Presenilin homologue Sel-12 is downregu-
lated by the Fbx protein Sel-10, a subunit of the SCF complex [93].
A
B
Fig. 2 APP Processing and signaling is regulated by neddylation. A. The C-terminal sequence of APP695 showing the lysine residues and the c-secre-
tase cleavage sites. B. The conservation of APP, APLP1, and APLP2. The human sequences were aligned and analyzed by Praline. *, the positions
of the APP lysine residues.
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Sel-10 interacts with PS1 and enhances PS1 ubiquitination, thus
decreasing cellular levels of c-secretase. Co-expression of Sel-10 and
APP in HEK293 cells alters the metabolism of APP and increases the
production of Ab peptides [94]. Along this line of evidence, it has
been demonstrated that BP1 suppression dramatically increases Ab
levels, especially the levels of Ab42, in neurons [76]. Together, these
data suggest that BP1-activated neddylation of Cul1 and activation of
SCF is necessary for the proper processing of APP.
Besides the role of BP1 in modulating c-secretase activity, BP1
may also control Ab42 degradation by activating a parkin-containing
ligase. Mutations in parkin cause autosomal recessive early onset PD
characterized by the loss of midbrain dopamine neurons [95]. Parkin
is a RING protein in the ubiquitin ligase that includes Cul1, Skp1, and
the Fbx/WD repeat protein hSel-10 [96, 97]. This Parkin-containing
ligase also polyubiquitinates misfolded proteins through a Lys-63-
linked ubiquitin chain [98, 99]. Parkin deletion in mutant tau mice
causes extensive amyloidosis [100]. Parkin expression has also been
shown to ubiquitinate intracellular Ab and promote Ab clear-
ance through proteasomal degradation and activation of autophagy
[101–103]. These data suggest that activation of the parkin-contain-
ing ligase may be beneficial.
The effect of the interaction between APP and BP1 likely depends
on cell and tissue environments and developmental stages. BP1 has
been shown to inhibit G1/S transition in ts41 cells [17], which sug-
gests that the BP1 pathway is critical for maintaining homeostasis of
neurons in response to signaling. However, this finding in ts41 cells
was challenged by a recent study showing that BP1 suppression
impedes G1/S transition in foetal neural stem cells [104]. The differ-
ent role of BP1 in the G1/S checkpoint of the cell cycle has not been
replicated by independent laboratories in ts41 cells or neural stem
cells. In Drosophila, overexpression of the APP-like protein APPL
inhibits neddylation whereas augmenting the BP1 pathway rescues
APPL-induced apoptosis [105]. This contrasts with our studies using
rodent primary neurons in which APP induces apoptosis in a BP1-
dependent pathway [49, 80]. These results may reflect the difference
between APPL and APP and/or experimental systems.
Neddylation in AD neurogenesis
If the functions of BP1 in cell cycle progression are applicable to neuro-
nal populations, one may expect that the neddylation pathway regulates
stem cell renewal. Currently, a BP1 KO animal model is not available,
but Uba3 deletion leads to embryonic lethality at the peri-implantation
stage [106]. This, together with the fact that BP1 is necessary for cell
cycle progression in ts41 cells, suggests that BP1 KO mice may be
embryonically lethal and that humans who harbor mutations that
jeopardize the function of BP1 in neddylation may not survive beyond
the fetus stage. Despite that one cannot observe the effect of BP1 on
neurogenesis in vivo and limited information is available from in vitro
studies, evidence suggests that the BP1 pathway plays pivotal roles in
neurogenesis by interacting with APP and PS1 (Fig. 4).
A B
Fig. 3 BP1 and nedd8 protein expression in mouse and human brains. A. BP1 was expressed in normal mouse brain hippocampus. Paraffin-embed-
ded, adult C57BL/6 mouse brain sections were immunostained with rabbit anti-BP1 (BP339) [19] coupled with Alexa fluor 564 goat anti-rabbit (Invi-
trogen). The nucleus was stained with DAPI. Some pyramidal cells were positive for BP1. Cells in the dentate granule cell layer, especially those
near the subgranular zone, were positive for BP1. B. Nedd8 expression in human control and AD brains. Nedd8 staining was present in the nucleus
in control hippocampal neurons, but it was localized in the cytoplasm in AD hippocampal neurons. Frozen sections were stained with rabbit
anti-nedd8 (Zymed).
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BP1-activated neddylation attenuates the signaling of EGFR and
APP and affects neuronal differentiation. EGFR attenuation inhibits
the cell cycle [107], which may be necessary for a neural progenitor
cell (NPC) to undergo differentiation. Growth factor withdrawal is a
prerequisite for NPC differentiation [108]. In this context, a higher
rate of neuronal differentiation is found in NPCs isolated from APP KO
mice when grown in culture [109]. Deletion of PS1 that abolishes
Ab40 production during development also increases neuronal differ-
entiation, which depletes NPCs [110]. Similarly, reduction of PS1 in
the adult brain increases neuronal differentiation [111]. These data
suggest that deletion of APP and PS1 abolishes the replication poten-
tial of the NPCs and leads to the default fate of differentiation. Since
BP1-activated neddylation downregulates EGFR and APP signaling,
neddylation may increase the potential for neuronal differentiation.
This appears to be the case since BP1 knockdown is shown to reduce
neuronal differentiation [112]. BP1 has also been shown to promote
neurogenesis induced by focal transient ischemia [113].
A characteristic of the APP KO mice is reduced body weight in the
adult animals [114, 115], which indicates impaired cell cycle progres-
sion and reduced NPC self-renewal. Perhaps APP deletion results in
the loss of a proliferative signal. The secreted, a-secretase cleavage
product of APP, sAPPa, behaves like a growth factor and stimulates
NPC proliferation (see recent review [116]). In addition, Ab peptides
also induces a strong proliferative effect in NPCs [117]. Meanwhile
low levels of monomeric Ab40 promotes neuronal differentiation
whereas low levels of Ab42 induces gliagenesis [117]. In contrast to
these positive effects of sAPPa and Ab peptides in NPCs, AICD has
been shown to attenuate NPC differentiation [109, 112]. To summa-
rize the data, the a-secretase cleavage pathway generates sAPPa that
favors NPC self-renewal (Fig. 4A) whereas the b- and c-secretase
pathway mainly produces Ab40 that promotes NPC differentiation
(Fig. 4B). BP1 downregulates AICD and ensures non-amyloidogenic
processing of APP, both of which promote neuronal differentiation.
Currently, how neurogenesis is affected in AD brains remains contro-
versial [118–120]. Clearly more research is warranted before we can
successfully apply stem cell therapies for treating neurodegeneration.
Conclusions
A major conclusion of this review is that dysfunction of neddylation is
involved in neurodegenerative diseases, especially in AD. BP1 resides
in the center of a large network of proteins that organize the post-
translational proteome by activating neddylation. Major substrates of
neddylation consist of CRLs and Type 1 transmembrane receptors.
BP1 and CRLs play major roles in APP trafficking and processing.
Specifically, by neddylating APP, BP1 regulates APP turnover and sig-
naling in neurons and NPCs.
This review also summarizes the intricate relationship between
Presenilin and BP1 in the regulation of APP processing and
suggests that NPCs are another major cell type affected by the
disease conditions. More research in this area will inform potential
stem cell therapies since neurogenesis is likely impaired by AD
conditions. The BP1 inhibitor MLN4924 is currently under clinical
trials and its potential impact on neuronal survival, neuronal sig-
naling, and NPC proliferation and differentiation should also be
examined if such drugs are used for prolonged treatments of can-
cer.
Overall, this review suggests that a better understanding of the
neddylation pathway is needed for discovering invaluable biomarkers
and specific drug targets against AD. At the molecular level, the avail-
able data suggest that APP regulates ubiquitination, but it remains to
be established what exactly APP does in the ubiquitination pathway.
Once we know the physiological function of APP, we may have
concrete strategies to prevent and treat AD.
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A B
Fig. 4 Neddylation regulates APP functions in NPC development. A. The
cleavage of APP by the a-secretase generates sAPPa that favors NPC
self-renewal. B. Production of Ab40 and Ab42 by the b- and c-secre-
tase cleavage promotes NPC differentiation. Ab40 promotes neurogene-
sis whereas Ab42 promotes gliagenesis [117]. BP1-activated
neddylation of APP supports the non-amyloidogenic processing of APP
and downregulates AICD. Both of these effects may promote neuronal
differentiation. Blue, APP, sAPPa, or AICD; red, Ab; purple, lysine resi-
dues in AICD; Black, unknown receptors or ligand.
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